NCT05290155View on ClinicalTrials.gov

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 4, 2022

Primary Completion Date

August 1, 2024

Study Completion Date

May 1, 2025

Conditions
T Lymphoblastic Leukemia/LymphomaT-cell Acute Lymphoblastic LeukemiaPeripheral T Cell LymphomaAngioimmunoblastic T-cell LymphomaAnaplastic Large Cell Lymphoma
Interventions
DRUG

anti-CD7 CAR-T cells

Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients

Trial Locations (1)

Unknown

Xianmin General Song, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER